Consensus Tarsus Pharmaceuticals, Inc.

Stocks

TARS

US87650L1035

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-06-26 EDT			5-day change	1st Jan Change
62.92 ^USD	-2.21%		-0.38%	-23.16%

05-14	Tarsus and John Cena partner to raise awareness of Demodex blepharitis, a common eyelid disease affecting approximately 25 million Americans	RE
05-12	Tarsus Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:40 PM

Evolution of the Average Target: Tarsus Pharmaceuticals, Inc.

Evolution of the Target Price: Tarsus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Tarsus Pharmaceuticals, Inc.

8f44a417e91b4396a7e2b564cfc01b._UdM9MQ2Du3FPEMVTOXrmP7WcTa-2NohJOEgSLEKLH0.jTI4svFAPpqPTAVcNpOP0sy7HH_h4bdTTbkXLNBrTiWEcHymi0x-27QNIA~53960c859e368bc072ee0323c15870ac

Analysts' recommendations: Tarsus Pharmaceuticals, Inc.

04-24	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $98 From $105, Maintains Outperform Rating	MT
04-23	Mizuho Trims Price Target on Tarsus Pharmaceuticals to $100 From $101, Keeps Outperform Rating	MT
03-26	Mizuho Lifts Price Target on Tarsus Pharmaceuticals to $101 From $100, Keeps Outperform Rating	MT
02-25	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating	MT
11-20	Mizuho Initiates Tarsus Pharmaceuticals at Outperform With $100 Price Target	MT
25-10-09	Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says	MT
25-10-09	BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80	MT
25-08-06	Tarsus Pharmaceuticals Q2 revenue beats expectations	RE
25-06-02	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $72, Maintains Outperform Rating	MT
25-02-03	BofA Adjusts Price Target on Tarsus Pharmaceuticals to $75 From $74	MT
25-01-22	Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $72 From $65, Keeps Outperform Rating	MT
24-11-14	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating	MT
24-08-09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $63 From $61, Maintains Outperform Rating	MT
24-05-09	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating	MT
24-02-29	Goldman Sachs Adjusts Price Target on Tarsus Pharmaceuticals to $30 From $19, Maintains Neutral Rating	MT
24-02-28	Oppenheimer Raises Tarsus Pharmaceuticals Price Target to $59 From $55, Maintains Outperform Rating	MT
23-11-20	Goldman Sachs Starts Tarsus Pharmaceuticals With Neutral Rating, $19 Price Target	MT
23-11-10	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $42, Keeps Buy Rating	MT
23-09-11	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $49 From $46, Maintains Buy Rating	MT
23-08-11	HC Wainwright Adjusts Tarsus Pharmaceuticals Price Target to $42 From $50, Maintains Buy Rating	MT
23-07-26	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $50 From $44, Maintains Buy Rating	MT
23-07-18	William Blair Initiates Tarsus Pharmaceuticals at Outperform Rating	MT
23-06-26	HC Wainwright Adjusts Price Target on Tarsus Pharmaceuticals to $44 From $40, Keeps Buy Rating	MT
23-06-16	Guggenheim Raises Price Target on Tarsus Pharmaceuticals to $42 From $40, Maintains Buy Rating	MT
23-05-18	Guggenheim Initiates Coverage on Tarsus Pharmaceuticals With Buy Rating, $40 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	TARSUS PHARMACEUTICALS, INC.					+49.57%
	REGENERON PHARMACEUTICALS, INC.					+31.66%
	UCB					+11.29%
	SAMSUNG BIOLOGICS CO.,LTD.					+54.77%
	CSL LIMITED					+21.77%
	BIOGEN INC.					+1.95%
	MODERNA, INC.					-34.22%
	INCYTE CORPORATION					-2.69%
	INNOVENT BIOLOGICS, INC.					+56.55%
	SWEDISH ORPHAN BIOVITRUM AB					+2.16%
	Average					+19.28%
	Weighted average by Cap.					+18.71%